Lenvima 14 mg

LENVIMA 14 MG capsules contain lenvatinib mesylate, a medication used to treat certain types of cancer. This oral medication is manufactured by Eisai Limited in Canada and is available in a pack size of 60 capsules (30 x 10 MG, 30 x 4 MG).

LENVIMA 14 MG capsules are primarily used in the treatment of advanced forms of thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. Lenvatinib mesylate works by inhibiting the growth of cancer cells. It is often prescribed as part of a comprehensive treatment plan, which may include other medications or therapies. Patients should consult their healthcare provider to determine if this medication is suitable for their specific condition.

Common effects of LENVIMA 14 MG capsules may include fatigue, diarrhea, decreased appetite, and high blood pressure. Some patients may also experience nausea, vomiting, and weight loss. These effects can vary in severity and duration. It is important to monitor for any unusual symptoms and report them to a healthcare professional.

LENVIMA 14 MG capsules should be handled with care and stored as directed. Patients should follow the prescribed dosage and administration instructions provided by their healthcare provider. It is important to inform your healthcare provider about any other medications you are taking to avoid potential interactions. Pregnant women or those planning to become pregnant should discuss the risks and benefits with their healthcare provider.

LENVIMA 14 MG capsules may interact with certain medications, including those that affect liver enzymes or blood pressure. Alcohol consumption should be avoided as it may exacerbate certain side effects. Patients should also be cautious when taking other medications that affect the immune system or blood clotting. Always consult a healthcare provider before starting or stopping any medication.